Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Next Previous
X
Search
Trial Profile

A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Satralizumab (Primary) ; Azathioprine; Mycophenolate mofetil; Prednisolone
  • Indications Neuromyelitis optica
  • Focus Adverse reactions; Registrational
  • Acronyms SAkuraMoon
  • Sponsors Roche

    • Most Recent Events

    • 14 Jun 2024 Status changed from active, no longer recruiting to completed.
    • 18 Apr 2024 Results of Updated Analysis of Long-term Efficacy of Satralizumab , presented at the 76th Annual Meeting of the American Academy of Neurology 2024
    • 13 Oct 2023 Results assessing the long-term efficacy of satralizumab in patients with aquaporin-4-IgG-seropositive (AQP4 IgG+) neuromyelitis optica spectrum disorder, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top